NEKTAR THERAPEUTICS
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
NKTR$37.78-0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity (Deficit) for the
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)
(In thousands, except share data)
| Common Stock · Treasury Stock | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares · Amount · Capital inExcess ofPar Value · AccumulatedOtherComprehensive Income/(Loss) · AccumulatedDeficit · TotalStockholders’Equity (Deficit) | |||||||||||
| Balance at December 31, 2024 | 12,385,001 | $1 | 552,307 | $(3,000) | $3,659,885 | $61 | $(3,596,210) | $60,737 | |||
| Shares issued under equity compensation plans | 21,709 | — | — | — | 7 | — | — | 7 | |||
| Stock-based compensation | — | — | — | — | 3,898 | — | — | 3,898 | |||
| Comprehensive income (loss) | — | — | — | — | — | (22) | (50,882) | (50,904) | |||
| Balance at March 31, 2025 | 12,406,710 | $1 | 552,307 | $(3,000) | $3,663,790 | $39 | $(3,647,092) | $13,738 | |||
| Shares issued under equity compensation plans | 50,542 | — | — | — | 211 | — | — | 211 | |||
| Stock-based compensation | — | — | — | — | 3,486 | — | — | 3,486 | |||
| Comprehensive income (loss) | — | — | — | — | (53) | (41,593) | (41,646) | ||||
| Balance at June 30, 2025 | 12,457,252 | $1 | 552,307 | $(3,000) | $3,667,487 | $(14) | $(3,688,685) | $(24,211) | |||
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)
(In thousands, except share data)
| Common Stock · Treasury Stock | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Capital inExcess ofPar Value | AccumulatedOtherComprehensive Income/(Loss) | AccumulatedDeficit | TotalStockholders’Equity | |
| Balance at December 31, 2025 | 20,378,832 | $2 | — | $— | $3,850,099 | $17 | $(3,760,286) | $89,832 |
| Shares issued under equity compensation plans | 130,034 | — | — | — | 4,055 | — | — | 4,055 |
| Stock-based compensation | — | — | — | — | 3,355 | — | — | 3,355 |
| Shares and pre-funded warrants sold in underwritten offering, net of underwriting discounts and offering costs of $28,134 | 7,637,931 | 1 | — | — | 431,865 | — | — | 431,866 |
| Shares sold under at-the-market offering, net of commissions and offering costs of $2,936 | 1,325,295 | — | — | — | 93,063 | — | — | 93,063 |
| Comprehensive income (loss) | — | — | — | — | — | (1,051) | (44,904) | (45,955) |
| Balance at March 31, 2026 | 29,472,092 | $3 | — | $— | $4,382,437 | $(1,034) | $(3,805,190) | $576,216 |
| Shares issued under equity compensation plans | 94,417 | — | — | — | 878 | — | — | 878 |
| Stock-based compensation | — | — | — | — | 3,365 | — | — | 3,365 |
| Shares sold in underwritten offering, net of underwriting discounts and offering costs of $23,324 | 4,062,500 | — | — | — | 350,426 | — | — | 350,426 |
| Shares sold under at-the-market offering, net of commissions and offering costs of $420 | 207,555 | — | — | — | 13,580 | — | — | 13,580 |
| Exercise of pre-funded warrants | 293,100 | — | — | — | — | — | — | — |
| Comprehensive income (loss) | — | — | — | — | — | (722) | (40,622) | (41,344) |
| Balance at June 30, 2026 | 34,129,664 | $3 | — | $— | $4,750,686 | $(1,756) | $(3,845,812) | $903,121 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.